RxDoctor Payments Data

Kanwal Nayyar, MD

Neurology · Mission Hills, CANPI 1043238371

Payments from drug & device makers

$88,338in general payments, 2019–2025

Across 1,076 payments — averaging $82.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Biogen$71K
  • UCB, Inc.$2K
  • AbbVie$2K
  • SK Life Science, Inc.$1K
  • Teva Pharmaceuticals USA, Inc.$1K
  • Novartis$1K
  • plus $10K from 50 others

What the payments were for

  • Consulting fees$12,72414%
  • Speaking & faculty fees$54,09161%
  • Travel & lodging$2,1952%
  • Food & beverage$19,04722%
  • Education$2800%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Biogen255$71,457
UCB, Inc.91$2,143
AbbVie(2 entities)73$1,731
SK Life Science, Inc.59$1,139
Teva Pharmaceuticals USA, Inc.24$1,027
Novartis59$1,020
MDD US Operations, LLC71$781
Sanofi31$644
Acadia Pharmaceuticals Inc28$550
Sunovion Pharmaceuticals Inc.25$503
Kyowa Kirin, Inc.18$414
Pfizer22$406
Livanova USA, Inc.13$406
Neurelis, Inc.22$377
Supernus Pharmaceuticals, Inc.46$377
Lilly USA, LLC20$376
Neurocrine Biosciences, Inc.16$371
Greenwich Biosciences, Inc.8$347
Bristol Myers Squibb15$337
Eisai Inc.13$312
Genentech USA, Inc.9$260
Amgen(2 entities)10$253
AstraZeneca7$235
ANI Pharmaceuticals, Inc.13$209
Johnson & Johnson10$205
Sumitomo Pharma America, Inc.11$198
Otsuka America Pharmaceutical, Inc.16$189
Aucta Pharmaceuticals, Inc.10$189
Medtronic(2 entities)5$188
EMD Serono, Inc.7$181
Lundbeck LLC7$169
Amneal Pharmaceuticals LLC7$169
Scilex Pharmaceuticals Inc.6$118
Argenx US, Inc.4$111
Avanir Pharmaceuticals, Inc.5$84
Boston Scientific3$83
Springworks Therapeutics, Inc.3$81
Merz Pharmaceuticals, LLC3$78
Cycle Pharmaceuticals Inc3$55
Biohaven Pharmaceuticals, Inc.3$55
Adamas Pharmaceuticals, Inc.3$54
CSL Behring2$53
Abbott2$50
Acorda Therapeutics, Inc3$43
Upsher-smith Laboratories LLC2$43
Tanabe Pharma America, Inc.2$38
Tonix Medicines, Inc.2$35
Takeda Pharmaceuticals U.S.A., Inc.1$28
GE HealthCare1$26
Forte Bio-pharma LLC1$25
Vertical Pharmaceuticals, LLC1$24
Biohaven Pharmaceutical Holding Company Ltd.1$23
Xeris Pharmaceuticals, Inc.1$22
Corium, LLC1$20
Arbor Pharmaceuticals, Inc.1$13
Collegium Pharmaceutical, Inc.1$12

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$88,338 in reported general payments places this provider in the 85th percentile of 1,996 neurology providers in California.

See all neurology providers in California

Medicare billing

Part B allowed, 2024
$59,683
Medicare patients
209
Services billed
406

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VumerityDiroximel Fumarate46$390,866
PrivigenImmun Glob G(Igg)/Pro/Iga 0-5012$240,211
Teriflunomide20$103,528
QuliptaAtogepant15$23,961
UbrelvyUbrogepant12$21,948
XcopriCenobamate15$18,891
AptiomEslicarbazepine Acetate14$18,015
Levetiracetam355$16,442
Gabapentin478$12,624
VimpatLacosamide11$12,386
Memantine Hcl343$11,330
Donepezil Hcl552$6,154
Oxcarbazepine18$5,601
Duloxetine Hcl195$5,598
Carbamazepine ErCarbamazepine30$5,216

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
BiogenVumerity$71,457$390,86646 claims
CSL BehringPrivigen$53$240,21112 claims
AbbVieQulipta, Ubrelvy$1,731$45,90927 claims
SK Life Science, Inc.Xcopri$1,139$18,89115 claims
Sunovion Pharmaceuticals Inc.Aptiom$503$18,01514 claims
UCB, Inc.Vimpat$2,143$12,38611 claims
PfizerDilantin$406$2,83414 claims
Upsher-smith Laboratories LLCTopiramate$43$2,562214 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,996 neurology providers in California.

Other neurology in Mission Hills

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →